/Insulet%20Corporation%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $20.2 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The insulin infusion systems maker is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Thursday, Aug. 7.
Ahead of the event, analysts expect PODD to report a profit of $0.93 per share on a diluted basis, up 69.1% from $0.55 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.
For the full year, analysts expect PODD to report EPS of $4.33, up 33.6% from $3.24 in fiscal 2024. Its EPS is expected to rise 25.4% year over year to $5.43 in fiscal 2026.
PODD stock has outperformed the S&P 500 Index’s ($SPX) 14.5% gains over the past 52 weeks, with shares up 45.7% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund’s (XLV) 8.3% dip over the same time frame.
Insulet's strong performance is driven by robust U.S. growth, expanding international demand, and the success of its Omnipod insulin delivery systems. With continued innovation and global expansion, the company is well-positioned for long-term growth in the diabetes care market, making it a promising investment in the medical technology sector.
On May 8, PODD reported its Q1 results, and its shares closed up more than 20% in the following trading session. Its adjusted EPS of $1.02 surpassed Wall Street's expectations of $0.81. The company’s revenue was $569 million, topping Wall Street forecasts of $542.1 million.
Analysts’ consensus opinion on PODD stock is bullish, with an overall “Strong Buy” rating. Out of 23 analysts covering the stock, 19 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” and two give a “Hold.” PODD’s average analyst price target is $343.77, indicating a potential upside of 19.9% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
